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Table 1. Dissociation constants of human and L. casei DHFR using the cen- 



















All experiments were performed at 10e4 M NADPH. Dissociation constants 
were measured by Scatchard analysis. Conditions for complex formation and 
processing for both methods are detailed in the text. 
actual amount of MTX bound to DHFR at a given ligand 
concentration. Exposure to charcoal for 1 min allowed com- 
plete adsorption of all unbound ligand while maintaining 
the maximum concentration of. ternary complex, as the 
complex was relatively stable for 3 min following charcoal 
exposure (Fig. 2), We applied this new technique to a study 
of MTX binding constants (Kv) to DHFR purified from 
both a human and a bacterial source and compared these 
results to those obtained in parallel experiments utilizing 
centrifugation to separate bound from free drug. As Table 
1 shows, the method used for measuring ternary complex 
formation produced constants of dissociation that differed 
by up to 70-fold, depending on the assay conditions and 
enzyme source. The lower affinity figure likely reflected the 
binding constant of MTX to DHFR at low concentrations 
of NADPH. 
The filtration method not only improved the accuracy of 
determination of binding constants but also enhanced the 
sensitivity by at least 5-fold. A gain in sensitivity also 
occurred in the MTX concentration range of lo-’ to 1O-9 M 
due to the greater steepness of the binding curve (Fig. 2). 
This range is important in that drug concentrations above 
10m8M are cytotoxic for bone marrow myeloid precursor 
and dividing cells of the gastrointestinal epithelium [7]. 
In summary, the use of rapid separation techniques that 
* Author to whom all correspondence should be 
addressed. 
minimize the exposure of the DHFR-NADPH-MTX com- 
plex to activated charcoal allows a more accurate measure- 
ment of this complex. This technique facilitates the study 
of kinetic interactions of DHFR with MTX and the 
measurement of MTX concentrations. 
Clinical Pharmacology Branch 
Division of Cancer Treatment 
National Cancer Institute 
Bethesda, MD 20205, U.S. A. 
JAMES C. DRAKE* 
CARMEN J. ALLEGRA 
BRUCE A. &ABNER 
REFERENCES 
1. U. Westphal, Steroid-Protein Interactions. Springer, 
New York (1971). 
2. S. Waxman and C. Schreiber, Blood 42, 281 (1973). 
3. C. E. Myers, M. E. Lippman, H. M. Eliot and B. A. 
Chabner, Proc. natn. Acad. Sci. U.S.A. 72,3683 (1975). 
4. B. T. Kaufman and V. F. Kemener, Archs Biochem. 
Biophys. 179, 420 (1977). 
5. G. Scatchard, Ann. N.Y. Acad. Sci. 51, 660 (1949). 
6. B. A. Kamen, W. Whyth-Bauer and J. R. Bertino, 
Biochem. Pharmac. 32, 837 (1983). 
7. B. A. Chabner and R. C. Young, J. clin. Invest. 52, 
1804 (1973). 
Biochemical Pharmacology, Vol. 35, No. 7. pp. 121C1216, 1986. OOO6-295@6 $3.00 + 0.00 
Printed in Great Britain. @ 1986 Pergamon Press Ltd. 
Genetic differences in inhibition of 2-aminofluorene N-acetyltransferase activity 
between C57BL/6J and A/J mice 
(Received 2 May 1985; accepted 20 September 1985) 
Competitive inhibition of one or more of the metabolic 
steps in the activation of chemical carcinogens is a potential 
chemopreventive mechanism. The first step in the meta- 
bolic activation of AF* to reactive electrophiles, and a 
potential point for control, is N-acetylation to AAF by liver 
NAT [ 11. Differences in AF NAT activity are under genetic 
control in C57BL/6J and A/J mice [2], and differences in 
human arylamine N-acetylating capacity have been cor- 
related with differences in susceptibility to urinary bladder 
* Abbreviations: AF, 2-aminofluorene; AAF, 2-acetyl- 
aminofluorene; NAT, N-acetyltransferase; PABA, p- 
aminobenzoic acid; MTX, methotrexate; NF, 2-nitro- 
fluorene; DlT, dithiothreitol; K,, inhibition constant; 
TCA, trichloroacetic acid; TFA, trifluoracetic acid; 
DMSO, dimethyl sulfoxide; and HPLC, high performance 
liquid chromatography. 
cancer [3-51. In the present study, we wanted to identify 
relatively non-toxic, preferably competitive inhibitors of 
liver AF NAT, and to determine if there was a differential 
susceptibility to the effect of these inhibitors between 
C57BL/6J and A/J mice. This paper presents evidence that 
the beta-carboline derivatives have no effect on NAT, and 
that PABA competitively inhibits, and folic acid and MTX 
noncompetitively inhibit NAT. In addition, there was a 
statistically significant difference in K, values for folic acid 
and MTX between C57BL/6J and A/J NAT. 
Materials and methods 
Chemicals. AF was purchased from K & K Laboratories, 
Plainview, NY; AAF from the Aldrich Chemical Co., 
Milwaukee, WI; acetyl CoA from P-L Biochemicals, Inc., 
Milwaukee, WI; folic acid from the Nutritional Biochemical 
Corp., Cleveland, OH; and PABA, MTX, harmine, har- 
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maline, harmol, norharman and DTT from the Sigma 
Chemical Co., St. Louis, MO. NF was donated by Dr. 
Charles King of the Michigan Cancer Foundation, Detroit, 
MI. All solvents were HPLC grade. 
Animals. Male C57BL/6J and A/J mice, ages 3-4 
months, were obtained from Jackson Laboratories, Bar 
Harbor, ME. Mice were housed two to four to a cage, 
allowed mouse chow and water ad lib., and maintained on 
a 12-hr light-dark schedule. 
Enzyme preparation. Mice were killed by cervical dis- 
location, and livers were removed and homogenized by 
hand in glass homogenizers in 4 vol. of 50 mM potassium 
ohosohate buffer, 1 mM D’IT, pH 7.4. Homogenates were 
centrifuged at 10,000 g for 20 mm; the supernacant fractions 
were centrifueed at 105,OOOn for 1 hr. The cvtosol was 
diluted 1: 1 wzh 50 mM pota&m phosphate buffer, 1 mM 
DTI’, pH 7.4, and used for all assays. All preparations were 
carried out at 4”. Protein concentrations were determined 
by method of Lowry ef al. [6]. 
Inhibition assay. PABA, folic acid, MTX, harmine, har- 
maline, harmol, and norharman were tested for their abili- 
ties to inhibit AF NAT activity. Initially, these inhibitors 
at a concentration of 5 mM were incubated with NAT and 
0.2 mM AF for 0. 1. 2. and 3 min. The comoounds with 
inhibitory capacity were studied further, and ii values and 
types of inhibition were determined. 
The reaction mixture (100 4) consisted of 20 4 AF, 10 fl 
inhibitor, and 50 fl enzyme. Following a 2-min pre- 
incubation at 37”, 20 ,nl acetyl CoA (final concentration of 
0.5 mM in reaction mixture) was added to begin the 
reaction. Acetyl CoA was omitted from controls. Tubes 
were incubated for 0, 1, 2, and 3 min, and the reaction was 
terminated by the addition of 10% cold TCA. Samples 
were spun for 1 min and frozen. 
For K, and type of inhibition determinations, six con- 
centrations of AF, ranging from 0.01 to 2mM, and four 
concentrations of inhibitors, 5, 0.5, 0.05, and 0.005 mM, 
were used. Neither AF nor the inhibitors were soluble at 
higher concentrations. All reaction tubes were incubated 
for 2 min and inhibitor was omitted from controls. 
Sample preparation. Samples were thawed the following 
dav and 1 N NaOH was added to increase the DH. NF 
(1he5 M) was added as an internal standard. Samples were 
extracted twice for 30 min each with ether (2 ml), evap- 
orated under a gentle stream of N,, and redissolved in 
0.5 ml of acetonitrile/water (70:30, v/v). 
HPLC analysis. AAF was determined by HPLC accord- 
ing to modifications of methods described by Stanley [7] 
and Raineri et al. [8]. A Varian instrument equipped with 
a variable wavelength detector set at 290nm was used. 
Separations were performed on a Whatman Cl8 Partisil, 
ODS-3, 10 pm reversed-phase column. AAF was eluted at 
approximately 9.4 min and NF at approximately 12.5 min 
by a IO-min linear gradient of TFA (O.l%)/acetonitrile 
(60:40) to 100% acetonitrile at a flow rate of 1 ml/min. 
AAF was quantitated by reference to an AAF/NF vs AAF 
standard curve. 
Treatment of data. Lineweaver-Burk plots were drawn 
for all inhibitors to determine the type of inhibition. Dixon 
plots were used to analyze and calculate K, values. K, 
differences were analyzed for significance by the chi-square 
test. 
Results and discussion 
N-Acetylation, being the first step in the metabolic acti- 
vation of AF, is a potential point for control of its activation. 
Theoretically, if AF NAT could be inhibited, formation of 
reactive metabolites and resultant DNA damage would be 
prevented or delayed. Thus, we wanted to find non-toxic 
competitive inhibitors of AF NAT. In addition, since gen- 
etic differences in AF NAT activity exist between C57BL/ 
65 and A/J mice, we wanted to determine whether the 
amount of inhibitor required to achieve inhibition differed 
between strains. 
Inhibition of AF NAT activity by harmine, harmaline, 
harmol, and norharman. It has been demonstrated that 
nonharman, a beta-carboline derivative produced by the 
pyrolysis of tryptophan, activates S9-mediated muta- 
eenicitv of AAF in the Ames test 191. Furthermore. Wright 
ir al. [l@ reported that the analogs, harmine and harmaline, 
inhibit NAT purified from rat and hamster liver. Thus, 
cytosolic preparations of NAT from C57BL/6J mice were 
incubated for 0, 1, 2, and 3min with 0.2mM AF in the 
presence of 5 mM harmine, harmaline, harmol, and nor- 
harman. However, none of these compounds inhibited AF 
NAT activity to any significant degree. In explanation of 
these discrepancies, it is possible that the mouse enzyme is 
different from the other two species and does not have the 
capability to bind these compounds. Furthermore, Wright 
et al. used purified enzyme, whereas we used a cytosolic 
preparation and the inhibitors may have undergone non- 
specific binding to proteins other than NAT, thereby reduc- 
ing the concentration available to inhibit NAT. 
Inhibition of AF NAT activity by PABA, folic acid, and 
MTX. Mandelbaum-Shavit and Blondheim [ll] showed 
that folic acid and MTX comoetitivelv inhibit PABA NAT 
activity in human blood. Furthermore, Andres ef al. 1121 
reported that MTX is a noncompetitive inhibitor for both 
acetvl CoA and arvlamines, and used MTX in an affinitv 
column to isolate and purify’NAT from pigeon liver. Thus, 
cytosolic preparations of NAT from C57BL/6J and A/J 
mice were incubated for 2 min with concentrations of AF 
ranging from 0.01 to 2mM in the presence of 0, 5, 0.5, 
0.05, and 0.005 mM PABA, folic acid, and MTX. Line- 
weaver-Burk plots show that PABA was a competitive 
inhibitor (Fig. l), and folic acid and MTX were non- 
competitive inhibitors of AFNAT (data not shown). Again, 
our results did not agree with those from previous inves- 
tigations. However, a different species and tissue were 
used. 
K, values, calculated from Dixon plots, are shown in 
Table 1. The K, for PABA was the same in both C57BL/ 
6J and A/J mice, and was approximately 6-16 times lower 
than the K, values for folic acid and MTX. The K, values 
for folic acid and MTX were significantly lower (2.5 times) 
in C57BL/6J than A/J mice with the K, values for MTX 
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Fig. 1. Competitive inhibition of AF NAT activity by 
PABA. Cytosolic preparations of NAT were incubated for 
2 min with concentrations of AF ranging from 0.01 to 
2 mM in the absence of inhibitor (0) or in the presence 
of 0.005mM PABA (A), 0.05mM PABA (m), 0.5mM 
PABA (a), and 5 mM PABA (x). AAF was quantitated 
by HPLC. 
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Table 1. K, values for inhibition of AF NAT activity 
K, (mM) 
Strain PABA Folic acid MTX 
C57BL/6J (3)* 0.16 * 0.01 1.06 ‘- 0.08 0.92 + 0.16 
A/J (3) 0.18 ? 0.01 2.80 ? 0.731 2.36 ” 0.17t 
Values are the mean 2 S.E.M. 
* Number of animals is given in parentheses. 
t Significantly different from C57BL/6J mice, P < 0.05. 
There are activity and structural differences in AF NAT 
between C57BL/6J and A/J mice [13] and, as a result, the 
A/J NAT required a higher concentration of inhibitor 
than the C57BL/6J NAT to achieve the same degree of 
inhibition. Recently, this same phenomenon has been 
observed by Szabo and Weber [14] who showed a dif- 
ferential response of C57BL/6J and A/J NAT to the inhibi- 
tor DMSO. However, PABA is a substrate with mono- 
morphic NAT activity for mouse liver NAT and, therefore, 
it is not surprising that the K, for PABA was the same in 
both strains. Nevertheless, NAT bound PABA with the 
greatest affinity and, thus, was the best inhibitor of AF 
NAT in both mouse strains. 
In summary, the beta-carboline derivatives failed to 
inhibit AF NAT activity. PABA was a competitive inhibi- 
tor, and folic acid and MTX were noncompetitive inhibitors 
of AF NAT for the acceptor amine. NAT from C57BL/6J 
and A/J mice bound PABA with the same affinity and more 
tightly than the other inhibitors. There was a differential 
* Present location: IIT Research Institute-Division L, 
10 West 35th St., Chicago, IL 60616. 
t Address correspondence to: Dr. Wendell W. Weber, 
6322 Medical Science Building 1, Department of Phar- 
macology, University of Michigan, Ann Arbor, MI 48109. 
sensitivity to the effect of folic acid and MTX between 
C57BL/6J and A/J mice; the K, value was significantly 
higher in A/J mice. 
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